Devyser Diagnostics AB (OSTO:DVYSR, Financial) is set to release its Q1 2025 earnings on Apr 29, 2025. The consensus estimate for Q1 2025 revenue is $57.18 million, and the earnings are expected to come in at -$0.56 per share. The full year 2025's revenue is expected to be $292.25 million and the earnings are expected to be $0.25 per share. More detailed estimate data can be found on the Forecast page.
Devyser Diagnostics AB (OSTO:DVYSR, Financial) Estimates Trends
Over the past 90 days, revenue estimates for Devyser Diagnostics AB (OSTO:DVYSR) have declined from $316.75 million to $292.25 million for the full year 2025, and from $419.50 million to $394.25 million for 2026. Similarly, earnings estimates have decreased from $0.33 per share to $0.25 per share for 2025, and from $3.34 per share to $3.22 per share for 2026.
Devyser Diagnostics AB (OSTO:DVYSR, Financial) Reported History
In the previous quarter ending on December 31, 2024, Devyser Diagnostics AB's (OSTO:DVYSR) actual revenue was $64.20 million, which missed analysts' revenue expectations of $65.03 million by -1.27%. Devyser Diagnostics AB's (OSTO:DVYSR) actual earnings were -$0.19 per share, which beat analysts' earnings expectations of -$0.57 per share by 66.67%. After releasing the results, Devyser Diagnostics AB (OSTO:DVYSR) was down by -7.19% in one day.
Devyser Diagnostics AB (OSTO:DVYSR, Financial) 12 Month Price Targets
Based on the one-year price targets offered by 3 analysts, the average target price for Devyser Diagnostics AB (OSTO:DVYSR) is $164 with a high estimate of $192 and a low estimate of $135. The average target implies an upside of 71.73% from the current price of $95.50.
Based on GuruFocus estimates, the estimated GF Value for Devyser Diagnostics AB (OSTO:DVYSR, Financial) in one year is $190.54, suggesting an upside of 99.52% from the current price of $95.50.
Based on the consensus recommendation from 3 brokerage firms, Devyser Diagnostics AB's (OSTO:DVYSR, Financial) average brokerage recommendation is currently 2.0, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
